Shots:
- Pfizer has reported its P-II trial data assessing the safety, tolerability & immunogenicity of a 4 dose series of PF-07872412 (25vPnC) vs 4 doses of PREVNAR 20 at mos. 2, 4, 6 & 12-15 in infants
- 25vPnC vaccine generated higher immune responses against serotype 3 vs Prevnar 20, with geometric mean titers 8.8-fold higher 1mos. after Dose 3 (4.22 vs 0.48) & ~15-fold higher 1mos. after Dose 4 (13.85 vs 0.92). Asset is expected to cover ~90% of disease-causing serotypes in pts (<5yrs.), incl. ~15% from serotype 3
- Based on P-II data & regulatory discussions, Pfizer initiated a pediatric P-III program in May 2026 of 25vPnC vs PCV20 in ~2,400 healthy children receiving vaccinations at 2, 4, 6, & 12–15mos. of age. Pfizer also expects to advance the adult 25vPnC candidate into clinical development by the end of 2026
Ref: Businesswire | Image: Pfizer | Press Release
Related News: Pfizer Reports the P-III (MagnetisMM-5) Trial Data on Elrexfio (Elranatamab) for R/R Multiple Myeloma (MM)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
